Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial
Bian et al., Signal Transduction and Targeted Therapy, doi:10.1038/s41392-025-02208-9
https://c19early.org/bian.html